These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 31880738

  • 1. Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination.
    Naleway AL, Crane B, Smith N, Francisco M, Weinmann S, Markowitz LE.
    Sex Transm Dis; 2020 Mar; 47(3):179-186. PubMed ID: 31880738
    [Abstract] [Full Text] [Related]

  • 2. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment.
    Guerra FM, Rosella LC, Dunn S, Wilson SE, Chen C, Deeks SL.
    Vaccine; 2016 Sep 07; 34(39):4678-4683. PubMed ID: 27527815
    [Abstract] [Full Text] [Related]

  • 3. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017.
    Checchi M, Mesher D, Mohammed H, Soldan K.
    Sex Transm Infect; 2019 Aug 07; 95(5):368-373. PubMed ID: 30723186
    [Abstract] [Full Text] [Related]

  • 4. Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women.
    Brotons M, Monfil L, Roura E, Duarte-Salles T, Casabona J, Urbiztondo L, Cabezas C, Bosch FX, de Sanjosé S, Bruni L.
    Prev Med; 2020 Sep 07; 138():106166. PubMed ID: 32565118
    [Abstract] [Full Text] [Related]

  • 5. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Nygård S, Nygård M, Orumaa M, Hansen BT.
    Vaccine; 2023 Aug 23; 41(37):5469-5476. PubMed ID: 37516572
    [Abstract] [Full Text] [Related]

  • 6. Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination.
    Tyros G, Mastraftsi S, Gregoriou S, Nicolaidou E.
    Int J STD AIDS; 2021 Jan 23; 32(1):4-13. PubMed ID: 33167803
    [Abstract] [Full Text] [Related]

  • 7. Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: a retrospective longitudinal population-based study.
    Guerra FM, Rosella LC, Dunn S, Wilson SE, Chen C, Deeks SL.
    BMJ Open; 2016 Mar 10; 6(3):e009914. PubMed ID: 26966057
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data.
    Thöne K, Horn J, Mikolajczyk R.
    BMC Infect Dis; 2017 Aug 14; 17(1):564. PubMed ID: 28806926
    [Abstract] [Full Text] [Related]

  • 9. Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.
    Flagg EW, Torrone EA.
    Am J Public Health; 2018 Jan 14; 108(1):112-119. PubMed ID: 29161070
    [Abstract] [Full Text] [Related]

  • 10. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
    Steben M, Ouhoummane N, Rodier C, Sinyavskaya L, Brassard P.
    J Med Virol; 2018 Mar 14; 90(3):592-598. PubMed ID: 28980715
    [Abstract] [Full Text] [Related]

  • 11. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
    Osmani V, Fett S, Tauscher M, Donnachie E, Schneider A, Klug SJ.
    BMC Cancer; 2022 Dec 09; 22(1):1293. PubMed ID: 36494790
    [Abstract] [Full Text] [Related]

  • 12. Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada.
    Righolt CH, Willows K, Kliewer EV, Mahmud SM.
    PLoS One; 2022 Dec 09; 17(4):e0267646. PubMed ID: 35472093
    [Abstract] [Full Text] [Related]

  • 13. Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006-2014: The impact of human papillomavirus vaccination.
    Shing JZ, Hull PC, Zhu Y, Gargano JW, Markowitz LE, Cleveland AA, Pemmaraju M, Park IU, Whitney E, Mitchel EF, Griffin MR.
    Papillomavirus Res; 2019 Jun 09; 7():141-149. PubMed ID: 30980966
    [Abstract] [Full Text] [Related]

  • 14. Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients.
    Woestenberg PJ, Guevara Morel AE, Bogaards JA, Hooiveld M, Schurink-van 't Klooster TM, Hoebe CJPA, van der Sande MAB, van Benthem BHB.
    Clin Infect Dis; 2021 Jul 15; 73(2):291-297. PubMed ID: 32421775
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ, King AJ, van der Sande MA, Donken R, Leussink S, van der Klis FR, Hoebe CJ, Bogaards JA, van Benthem BH, Medical Microbiological Laboratories, Public Health Services.
    J Infect; 2017 Apr 15; 74(4):393-400. PubMed ID: 28126492
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Incidence of anogenital warts in Germany: a population-based cohort study.
    Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E.
    BMC Infect Dis; 2010 Dec 23; 10():360. PubMed ID: 21182757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.